Vaccination with inhibin-α provides effective immunotherapy against testicular stromal cell tumors
Abstract Background Testicular cancer is the most common male neoplasm occurring in men between the ages of 20 and 34. Although germ-line testicular tumors respond favorably to current standard of care, testicular stromal cell (TSC) tumors derived from Sertoli cells or Leydig cells often fail to res...
Main Authors: | Robert Aguilar, Justin M. Johnson, Patrick Barrett, Vincent K. Tuohy |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2017-04-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40425-017-0237-2 |
Similar Items
-
A comparison of stage-specific all-cause mortality between testicular sex cord stromal tumors and germ cell tumors: results from the National Cancer Database
by: Kyle B. Zuniga, et al.
Published: (2020-04-01) -
Primary carcinoid or sex cord-stromal tumor of the testis. A case report
by: Ali Emadi Torghabeh, et al.
Published: (2023-01-01) -
Tumores testiculares na infância
by: Roni Leonardo Teixeira, et al. -
Inhibin B in stromal-cell ovarian tumors
by: N. V. Lyubimova, et al.
Published: (2020-03-01) -
Simultaneous Sertoli Cell-Only Syndrome and Leydig Cell Tumor in a Patient with Azoospermia: A Rare Case Report
by: Rawa Bapir, et al.
Published: (2022-12-01)